Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 9/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | GOT1 | P17174 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920000 | 0.80 | AKT2 (0.69) | AKT2GSK3BAKT1PBK | |
| SCHEMBL4779830 | 0.77 | AKT2 (0.52) | AKT2GSK3BAKT1ROCK2NUDT1 | |
| SCHEMBL4779828 | 0.77 | AKT2 (0.52) | AKT2GSK3BAKT1ROCK2NUDT1 | |
| SCHEMBL4919196 | 0.76 | AKT2 (0.61) | AKT2GSK3BAKT1NUDT1PBK | |
| SCHEMBL4776800 | 0.76 | AKT1 (0.42) | AKT2KITBTKAKT1BCDIN3D | |
| SCHEMBL4780166 | 0.73 | AKT1 (0.63) | AKT2AKT1ROCK2 | |
| SCHEMBL4725174 | 0.73 | AKT1 (0.63) | AKT2AKT1ROCK2 | |
| SCHEMBL4778819 | 0.72 | AKT1 (0.59) | AKT2AKT1 | |
| SCHEMBL1002759 | 0.68 | AKT2 (1.00) | AKT2GSK3BAKT1ROCK2PBK | |
| SCHEMBL857777 | 0.68 | PTK6 (0.61) | BTKBRAFKDRMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT2 1098/4885KIT 111/4885BTK 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.